Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03582826 · ClinicalTrials.gov registry record · NA

Microbial Basis of Systemic Malodor and "People Allergic To Me" Conditions

A NA study of Nutritional and Metabolic Diseases, sponsored by Mebo Research.

Completed
Registry status
NA
Development phase
125
Enrollment target
2
Study locations

NCT03582826: Completed NA study of Nutritional and Metabolic Diseases, sponsored by Mebo Research.

NCT03582826 is a NA study of Nutritional and Metabolic Diseases that has completed, run by Mebo Research. The registered enrollment target is 125 participants, above the 51-participant average among 4 other Nutritional and Metabolic Diseases trials with a reported enrollment target (145% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03582826, a NA study of Nutritional and Metabolic Diseases, has completed, sponsored by Mebo Research.

COMPLETED
Registry status
NA
Development phase
125 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to identify microbial signatures associated with remission and recurrence of idiopathic malodor and PATM conditions.

Primary Outcome

Abundance \[operational taxonomic units\]

Interventions

  • BEHAVIORAL Nutritional counselling
  • BEHAVIORAL Stress-reduction counseling

Study Locations (2)

Florida

  • MeBO Research - Miami

England

  • MeBO Research LTD - London

Trial Details

FieldValue
Enrollment Target 125 participants
Start Date 2018-06-16
Est. Completion 2020-02-10
Phase NA
Mebo Research

3 total trials

What the finished NCT03582826 record still lists

NCT03582826 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, above the 51-participant average among 4 other Nutritional and Metabolic Diseases trials with a reported enrollment target (145% higher).

The record links to 1 condition, with Nutritional and Metabolic Diseases appearing as the primary indexed condition, and to 2 interventions - of which Nutritional counselling is the first listed.

NCT03582826 reports a single indexed study location in Florida, England.

Frequently Asked Questions

What is clinical trial NCT03582826 about?

NCT03582826 is a clinical study titled "Microbial Basis of Systemic Malodor and "People Allergic To Me" Conditions". The purpose of this study is to identify microbial signatures associated with remission and recurrence of idiopathic malodor and PATM conditions.

What is the current status of trial NCT03582826?

This trial is currently completed. It is a NA study. The enrollment target is 125 participants. The study started on 2018-06-16. Estimated completion is 2020-02-10.

What conditions does trial NCT03582826 study?

This clinical trial studies the following conditions: Nutritional and Metabolic Diseases.

What interventions are being tested in trial NCT03582826?

The interventions under investigation include: Nutritional counselling (BEHAVIORAL), Stress-reduction counseling (BEHAVIORAL).

Who is sponsoring clinical trial NCT03582826?

This trial is sponsored by Mebo Research, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03582826 being conducted?

This trial has 2 study locations across Florida, England. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Nutritional and Metabolic Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02717039 · 125 participants

    Pharmacogenomics of Heparin-Induced Thrombocytopenia

  • NCT02763033 · 125 participants · Phase 2

    Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients

  • NCT02793999 · 125 participants

    Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia

  • NCT03003299 · 125 participants · NA

    PARTNER 3 Trial - Aortic Valve-in-Valve

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03582826, the US trial registry maintained by the National Library of Medicine. NCT03582826 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.